<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>American Funds 2035 Target Date Retirement Fund Class R-1 — News on 6ix</title>
<link>https://6ix.com/company/american-funds-2035-target-date-retirement-fund-class-r-1</link>
<description>Latest news and press releases for American Funds 2035 Target Date Retirement Fund Class R-1 on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/american-funds-2035-target-date-retirement-fund-class-r-1" rel="self" type="application/rss+xml" />
<item>
<title>Bexil Corporation Announces 2026 Tender Offer</title>
<link>https://6ix.com/company/american-funds-2035-target-date-retirement-fund-class-r-1/news/bexil-corporation-announces-2026-tender-offer</link>
<guid isPermaLink="true">https://6ix.com/company/american-funds-2035-target-date-retirement-fund-class-r-1/news/bexil-corporation-announces-2026-tender-offer</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>WALPOLE, NH / ACCESS Newswire / April 22, 2026 / Bexil Corporation (OTCID:BXLC) ("Bexil" or the "Company") today announced that it invites its stockholders to</description>
</item>
<item>
<title>Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/american-funds-2035-target-date-retirement-fund-class-r-1/news/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/american-funds-2035-target-date-retirement-fund-class-r-1/news/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused</description>
</item>
</channel>
</rss>